NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the
Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as
monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX
FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the
recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the
Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as
monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX
FASPRO TM), or NKTR-255 administered as a doublet with rituximab.
This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in
combination with daratumumab or rituximab.